Is severe rejection an indication for retransplantation?

Transplantation Proceedings

Volumn 32, Issue 6, 2000, Pages 1201-

  Kato, T ^a   Berho, M ^a   Weppler, D ^a   Ruiz, P ^a   Pinna, A D ^a   Khan, F A ^a   Nery, J R ^a   Tzakis, A G ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TSUKUBAENOLIDE;

CONFERENCE PAPER; DISEASE SEVERITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INTESTINE RESECTION; INTESTINE TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; MUROMONAB-CD3; REOPERATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; VISCERA;

EID: 0343714733     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(00)01184-2     Document Type: Conference Paper

References (2)

1. Tzakis A.G., Romero R., Weppler D., et al. Graft. 2:1999;116.
2. Misiakos E., Weppler D., Bakonyi A., et al. Transplant Proc. 31:1999;569.